The signal was always there. In 2026, we can finally read it.

A woman in her forties sat across from me with a diagnosis of stage III colon cancer. Her ferritin had been low for six years. Three different physicians had prescribed iron. Nobody had asked where the blood was going.

Details are changed. I have seen some version of this story hundreds of times. The biology was speaking long before the diagnosis. The system was not built to listen.

That is the problem prevention care exists to solve, and 2026 is the year it stopped being optional.

Cancer does not arrive without warning

Most cancers take years to become visible on a scan. Along the way they leave traces: a lab value drifting in the wrong direction, a family history nobody mapped, a germline mutation nobody tested for, a tumor DNA fragment circulating in blood at a concentration no human eye could detect.

The numbers on what this costs are not subtle. The American Cancer Society estimates that roughly 4 in 10 cancer cases in the United States are attributable to modifiable risk factors. For colorectal cancer, the five-year survival rate is about 91 percent when the disease is caught while still localized and about 13 percent once it has spread, according to the National Cancer Institute’s SEER program. That gap is not a treatment gap. It is a detection gap.

And detection has a hereditary layer that is almost entirely unmanaged. About 1 in 279 people carries a Lynch syndrome mutation, which raises lifetime colorectal cancer risk to roughly 10 to 60 percent depending on the gene, many times the general population rate. BRCA1 carriers face a lifetime breast cancer risk of up to 72 percent. The majority of carriers are never identified. They learn their status the way my patient learned hers, at diagnosis.

What changed in 2026

For most of my career, the limiting factor in prevention was not knowledge. It was bandwidth. A physician can hold a few dozen variables in working memory during a visit. A patient’s actual risk picture involves hundreds: germline variants, polygenic risk, inflammatory markers, iron and metabolic trends, screening history, exposures, family pedigree across three generations.

AI systems now read that whole picture at once. Multi-cancer early detection tests analyze methylation patterns across tens of thousands of genomic regions in a single blood draw. Risk models integrate genomics, labs, and lifestyle into a trajectory rather than a snapshot. Pattern recognition that once required a research lab runs in the background of a clinic visit.

I have been building toward this for a long time. More than a decade ago, with NIH funding, I built a machine learning model that predicted which sickle cell patients would be readmitted to the hospital. The model worked. What struck me was that the signal had been sitting in the record the entire time. Nobody had been assigned to read it.

Later, at Genentech, I led tumor-agnostic clinical trials and worked on the programs that moved immunotherapy and precision oncology from research concept to approved standard of care. The lesson was the same at a different scale. The biology was knowable earlier than we were acting on it.

What prevention care actually looks like

Prevention care is a longitudinal relationship with a specialist who owns your risk picture and updates it as your biology and the science evolve. It is not a wellness panel, a one-time genetic test, or a screening reminder.

At BioNurture it runs in a specific order.

Foundation first. The validated screening and risk assessment that the evidence actually supports: mammography and colonoscopy at the right intervals for your risk, cervical and lung screening where indicated, a three-generation family pedigree, germline testing when criteria are met. These are the interventions with the strongest cancer-specific evidence, and most adults are behind on at least one.

Then the intelligence layer. Hereditary risk interpreted by an oncologist. Blood work read for trajectory, not just today’s value. Advanced tools like multi-cancer blood tests and whole-body imaging considered where they add information, and graded honestly, because every test we recommend gets scored on whether it is analytically valid, clinically valid, and clinically useful. A test that fails any of those is not on your plan.

Then the plan evolves. Risk is not static. A new family diagnosis, a new biomarker trend, a new piece of evidence changes what the right next step is. A specialist who follows you over years can act on that. A portal result cannot.

Who this is for

Anyone who wants to know their risk and act on it. You do not need a mutation or a family history to qualify. You need a reason to want the answer before a diagnosis defines the conversation.

The system was built to respond to cancer once it declares itself. Prevention care is what happens when a specialist takes responsibility for everything before that moment.

The signal has been there your whole life. Someone trained to read it should be in the room.

BioNurture provides specialist-led cancer prevention, survivorship, and hematology care by telemedicine in Texas and Florida. Apply for membership at bionurture.com. Physicians can refer a patient at bionurture.com/referrals.

Sources: American Cancer Society, Cancer Facts and Figures; NCI SEER Cancer Stat Facts, Colorectal Cancer; Win AK et al., Cancer Epidemiology, Biomarkers and Prevention (Lynch syndrome prevalence); Kuchenbaecker KB et al., JAMA 2017 (BRCA penetrance).